Health care in India is largely unaffordable, says IMS survey

22 July 2013

Significant challenges persist in providing quality health care on an equitable, accessible and affordable basis across all regions and communities in India, according to a new IMS Institute for Healthcare Informatics study.

The study, Understanding Healthcare Access in India: What is the Current State?, reports that a 40%-45% reduction in out-of-pocket expenditures for both outpatient and inpatient treatments can be attained through a holistic approach addressing four critical, interrelated dimensions of health care access. Those components are: physical accessibility and the location of health care facilities; availability and capacity of needed resources; quality and functionality of service required for patient treatment; and affordability of treatment relative to a patient’s income. The study was based on 15,000 households in rural and urban areas across 12 states. Information was supplemented by interviews with more than 1,000 doctors and experts.

Murray Aitken, executive director, IMS Institute for Healthcare Informatics, said: “While expanding health care access is a critical priority for both the Indian government and the private sector, the gap between aspiration and today’s reality is all too apparent. Challenges with resourcing and financing the public sector health infrastructure have a significant impact on the availability of health care workers and contribute to low-quality perceptions of public health facilities. This leads the rural-poor population to seek costlier treatment options – and adversely impacts overall health care access.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics